IL17A and hepatocellular carcinoma: Researchers showed that acetate itself is able to downregulate ILC3 functions by blocking HDAC activity; thus, they documented that the combination of acetate plus anti-PD-1 therapy could enhance the immune response in HCC mice models receiving ICIs, decreasing IL-17A mRNA levels [139].